Regulatory approval
Published by the Health Service Executive. Approved
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.
This is written in the approval document.
Reimbursement
CDS
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | ER positive, PR positive | Invasive Breast Carcinoma | Letrozole | |
| HSE (1) | ER positive | Invasive Breast Carcinoma | Letrozole | |
| HSE (1) | PR positive | Invasive Breast Carcinoma | Letrozole |
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2018-11-11 | Health Service Executive | Indication approved for reimbursement. |